AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JAN 8 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - A novel vaccine against Neisseria meningitidis elicits a protective humoral response in human infants, researchers in the United States report.
Kenneth T. Mountzouros and colleagues working at Wyeth Research in West Henrietta, New York, assessed the efficacy of a glycoconjugate N. meningitidis vaccine.
Antibodies produced after immunization with this vaccine candidate protected rats against bacterial meningitis, Mountzouros and coauthors found.
The researchers measured anti-N. meningitidis serogroup C capsular polysaccharide (PS) immunoglobulin G (IgG) levels in pooled serum samples from immunized infants. These serum pools contained up to 17.31 micrograms/mL of N. meningitidis-specific IgG, which showed normal function in a serum bactericidal assay (SBA), according to the report.
Moreover, the IgG antibodies found in serum from immunized infants significantly lowered N. meningitidis levels after passive transfer to newborn rats. Bacteremia reductions of at least 2 log units were seen in almost 95% of rat neonates treated with 0.031 microgram or greater IgG doses, study data showed.
...
Source: HighBeam Research, Bacterial meningitis vaccine elicits protective antibody production.